Phosphagenics pockets $18M; Rebiotix seeks $25M for fecal transplants;

@FierceBiotech: EuroBiotech: U.K. pols ready for $PFE's return, $AZN cozies up to EU academia, Israeli biotech upsizes IPO. Report | Follow @FierceBiotech

@JohnCFierce: Parting thought on $SRPT: Stock moves don't tell the whole story, folks. More | Follow @JohnCFierce

@DamianFierce: The "spinversion," a clever new way for companies to cut taxes but spare themselves the fallout of expatriation. Story via Bloomberg | Follow @DamianFierce

@EmilyMFierce: Ongoing Ebola outbreak sparks debate on experimental vaccine testing. Article from FierceVaccines | Follow @EmilyMFierce

> Australian biotech Phosphagenics has raised $18 million in a private placement. News

> Rebiotix, a developer of fecal-transplant therapies, is raising $25 million to support its treatment for C. difficile. Article

> Robotic exoskeleton outfit ReWalk Robotics is seeking $58 million in an IPO. Story

Medical Device News

@FierceMedDev: Smith & Nephew partners with startup for knee surgical system. More | Follow @FierceMedDev

@StacyALawrence: FDA clears oral sleep apnea device, as search for CPAP alternatives continues. Story | Follow @StacyALawrence

@VarunSaxena2: Cohen: uterine sarcomas often don't cause symptoms; pathology needed for diagnosis, imaging helpful, but not always accurate. | Follow @VarunSaxena2

@MichaelGFierce: MIT, MicroCHIPS develop remote-controlled contraceptive with on-off delivery. Article | Follow @MichaelGFierce

@EmilyWFierce: San Francisco gynecologist steps down from FDA panel the day before power morcellator hearings. Story via The Wall Street Journal (sub. req.) | Follow @EmilyWFierce

> ReWalk Robotics marches to market with $58M IPO. Story

> Philips Healthcare chief DiSanzo out in management shakeup. News

> Day One: Inside the FDA power morcelletor panel. Report

> Patent 'troll' legislation passes U.S. House subcommittee with some industry support. Article

Pharma News

@FiercePharma: Top-read on FierceVaccines yesterday: Could soaring vaccine prices spark Sovaldi-style payer pushback? Story | Follow @FiercePharma

@EricPFierce: Weak link in the supply chain. Pharmacist walks out of NY hospital with 1,500 oxycodone tabs. News | Follow @EricPFierce

@CarlyHFierce: Remember that time the NIH found smallpox samples? More | Follow @CarlyHFierce

> Questcor comes clean on adverse effects of beleaguered drug Acthar. Article

> Sun issues third recall since announcing deal to buy Ranbaxy. Story

> France health minister says EU will fight price of Gilead's Sovaldi. News

Suggested Articles

In this week's EuroBiotech Report, Sitryx inks Lilly deal, Genfit downplays COVID-19 impact on NASH data and Gilead tests remdesivir in U.K.

Amgen and new partner Adaptive Biotechnologies are the latest pharma-biotech duo joining forces against the pandemic.

In our EuroBiotech roundup this week, AM-Pharma raises €23 million, Nordic Nanovector makes cuts and Neurimmune, Ethris plan COVID-19 trial.